Gilead’s Twice-Yearly Shot Shows 100% Efficacy in Phase III HIV Trial in Women | BioSpace

Published: Jun 20, 2024 By Kate Goodwin

Gilead HQ/iStock, Sundry Photography

Pictured: Signage outside Gilead’s headquarters in California/iStock, Sundry Photography

Gilead Sciences’ antiviral demonstrated 100% efficacy for HIV prevention in cisgender women in Phase III trial results announced Thursday. The twice-yearly lenacapavir shot proved superior to Gilead’s already-approved oral medicines for HIV prevention, Truvada and Descovy. 

In the PURPOSE 1 trial, zero cases of HIV infection occurred among 2,134 women in the lenacapavir group, compared to 16 cases in the 1,068 women in the Truvada arm and 39 incidents among 2,136 women treated with Descovy. The long-acting shot was well-tolerated with no significant safety concerns, according to Gilead. 

“To have no infections in over 2,000 women… that’s a remarkable result,” Joe Eron, principal investigator at the HIV/AIDS Clinical Research Unit at University of North Carolina-Chapel Hill, told STAT…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks